Brought to you by 
Horizon pays $800mm to acquire orphan drug company Raptor
08 Sep 2020
Executive Summary
Horizon Pharma PLC acquired all outstanding shares of public biotech Raptor Pharmaceutical Corp. (rare disease therapeutics) for $9 apiece in cash (a 21% premium), valuing the transaction at $800mm, or over eight times Raptor's 2015 revenues of $94.2mm. Horizon will finance the purchase (expected to close in Q4 2016) with cash on hand and a planned $675mm debt financing.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Horizon pays $800mm to acquire orphan drug company Raptor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice